Mycotic infections in rheumatology
https://doi.org/10.14412/1996-7012-2017-2-18-24
Abstract
Invasive mycoses are becoming a more relevant problem in modern rheumatology. There are difficulties in the lifetime diagnosis and treatment of mycoses in patients with rheumatic diseases. The significance of this issue increases considerably due to the active clinical introduction of biological agents. The paper provides general information on the clinical presentation, diagnosis, and therapy of the most common mycoses.
About the Authors
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
G. M. Tarasova
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
D. V. Bukhanova
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
References
1. Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med Wkly. 2016;146:w14281. doi: 10.4414/smw.2016.14281
2. Gregg KS, Kauffman CA. Invasive Aspergillosis: Epidemiology, Clinical Aspects, and Treatment. Semin Respir Crit Care Med. 2015;36(5):662-72. doi: 10.1055/s-0035- 1562893.
3. Wang LR, Barber CE, Johnson AS, Barnabe C. Invasive fungal disease in systemic lupus erythematosus: A systematic review of disease characteristics, risk factors, and prognosis. Semin Arthritis Rheum. 2014; 44(3):325-330. doi: 10.1016/j.semarthrit. 2014.06.001.
4. Ishiguro T, Takayanagi N, Takaku Y, et al. Combined Allergic Bronchopulmonary Aspergillosis and Eosinophilic Granulomatosis with Polyangiitis: Three Cases and a Review of the Literature. Intern Med. 2016;55(7):793-7. doi: 10.2169/internalmedicine.55.5431
5. Vallabhaneni S, Chiller TM. Fungal Infections and New Biologic Therapies. Curr Rheumatol Rep. 2016;18(5):29. doi: 10.1007/ s11926-016-0572-1
6. McCarty TP, Pappas PG. Invasive Candidiasis. Infect Dis Clin North Am. 2016;30(1):103-24. doi: 10.1016/j. idc.2015.10.013
7. Pеrez-Sola MJ, Torre-Cisneros J, Pеrez-Zafrilla B et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clint (Barc). 2011;137(12):533-40. doi: 10.1016/j. medcli.2010.11.032.
8. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br J Dermatol. 2016 Aug 31. doi: 10.1111/bjd.15015. [Epub ahead of print].
9. Tattevin P, Revest M, Lefort A, et al. Fungal endocarditis: current challenges. Int J Antimicrob Agents. 2014;44(4):290-4. doi: 10.1016/j.ijantimicag.2014.07.003
10. Веселов АВ, Козлов РС. Инвазивный кандидоз: современные аспекты эпидемиологии, диагностики, терапии и профилактики у различных категорий пациентов (в вопросах и ответах). Клиническая микробиология и антимикробная химиотерапия. 2016;18 (Прил 2):1-103. [Veselov AV, Kozlov RS. Invasive candidiasis: modern aspects of epidemiology, diagnosis, therapy and prevention in different categories of patients (questions and answers). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2016;18 (Suupl 2):1-103. (In Russ.)].
11. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50. doi: 10.1093/cid/civ933.
12. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435-86. doi: 10.1161/CIR. 0000000000000296
13. Koehler P, Tacke D, Cornely OA. Aspergillosis of bones and joints – a review from 2002 until today. Mycoses. 2014 Jun; 57(6):323-35. doi: 10.1111/myc.12165. Epub 2014 Jan 8.
14. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi: 10.1093/cid/ciw326
15. Taroumian S, Knowles SL, Lisse JR, et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2012;64(12): 1903-9. doi: 10.1002/acr.21784.
16. Galgiani JN, Ampel NM, Blair JE. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis. 2016;63(6):e112-46. doi: 10.1093/cid/ciw360
17. Olson TC, Bongartz T, Crowson CS, et al. Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009. BMC Infect Dis. 2011 May 23;11:145. doi: 10.1186/1471- 2334-11-145.
18. Vergidis P, Avery RK, Wheat LJ. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015;61(3):409-17. doi: 10.1093/cid/civ299
19. Riddell J, Kauffman CA, Smith JA, et al. Histoplasma capsulatum endocarditis: multicenter case series with review of current diagnostic techniques and treatment. Medicine (Baltimore). 2014;93(5):186-93. doi: 10.1097/ MD.0000000000000034
20. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181-94.
21. Liao TL, Chen YM, Chen DY. Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. Clin Microbiol Infect. 2016;22(9):815. e1-815.e3. doi: 10.1016/j.cmi.2016.05.030
22. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26(5):663-70. doi: 10.1007/ s10067-006-0441-9
23. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jirovecii pneumonia following Rituximab treatment in Wegener's Granulomatosis. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1661-4. doi: 10.1002/acr.20279. Epub 2010 Jun 25.
24. Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford). 2008;47(8): 1256-7. doi: 10.1093/rheumatology/ken234
25. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780-9.
26. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002;34(8):1098-107.
27. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust. 1995;162(5):233-5.
28. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010;37(4):686-8. doi: 10.3899/ jrheum.091426.
29. Grubbs JA, Baddley JW. Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep. 2014;16(10):445. doi: 10.1007/s11926-014-0445-4
30. Appenzeller S, Amaral TN, Amstalden EM, et al. Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literature. Clin Rheumatol. 2006;25(6):926-8.
31. Васильева НВ, Климко НН, Цинзерлинг ВА. Диагностика и лечение инвазивных микозов: современные рекомендации. Вестник СПб МАПО. 2010;2(4):5-18. [Vasil'eva NV, Klimko NN, Tsinzerling VA. Diagnosis and treatment of invasive fungal infections: current recommendations. Vestnik SPb MAPO. 2010;2(4):5-18. (In Russ.)].
Review
For citations:
Belov BS, Tarasova GM, Bukhanova DV. Mycotic infections in rheumatology. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2017;11(2):18-24. (In Russ.) https://doi.org/10.14412/1996-7012-2017-2-18-24
Views:
1304
Email this article 